Pulse Biosciences, Inc. PLSE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.30% | -20.89% | -23.64% | 47.53% | 82.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.79% | 4.86% | -8.61% | 49.78% | 72.91% |
| Operating Income | -24.65% | -2.71% | 9.91% | -49.15% | -72.91% |
| Income Before Tax | -28.64% | -10.63% | 10.07% | -52.88% | -68.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.64% | -10.63% | 10.07% | -52.88% | -68.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.64% | -10.63% | 10.07% | -52.88% | -68.39% |
| EBIT | -24.65% | -2.71% | 9.91% | -49.15% | -72.91% |
| EBITDA | -25.08% | -2.91% | 9.91% | -50.52% | -75.03% |
| EPS Basic | -25.06% | -9.23% | 17.67% | -38.58% | -43.09% |
| Normalized Basic EPS | -25.04% | -5.43% | 17.67% | -38.52% | -43.17% |
| EPS Diluted | -25.06% | -9.23% | 17.67% | -38.58% | -43.09% |
| Normalized Diluted EPS | -25.04% | -5.43% | 17.67% | -38.52% | -43.17% |
| Average Basic Shares Outstanding | 2.86% | 1.29% | 9.24% | 10.35% | 17.66% |
| Average Diluted Shares Outstanding | 2.86% | 1.29% | 9.24% | 10.35% | 17.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |